Scientific article

The article by Lu et al. reports an in vitro study, conducted to determine whether high-fluence PACK-CXL can be accelerated while still maintaining its antibacterial efficacy. The study found that high-fluence PACK-CXL did indeed decrease the bacterial concentration of several clinically significant bacterial strains, including S. aureus, P. aeruginosa, and S. epidermidis. These strains are commonly implicated in bacterial keratitis and contact lens-associated keratitis. Furthermore, the authors found that higher total fluence PACK-CXL protocols led to a corresponding increase in bacterial killing ratio (BKR).
Keratoconus and Down Syndrome: How effective is CXL at treating KC in Down Syndrome? This is the first clinical trial to answer the question.
Our latest review on "CXL in thin corneas". It describes all current approaches how to treat thin keratoconus corneas using corneal cross-linking, including our original approach of swelling the cornea and our latest approach, the sub400 protocol.
High fluence PACK-CXL has progressed a great deal since it was first developed (1) as a treatment for infectious keratitis and corneal ulcers
A literature analysis that showed that Farhad Hafezi is the world's top ranked author in CXL- and this helps make Switzerland a world leader!
Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.
PACK-CXL is safe for use in bacterial keratitis cases. It also seems to add value in reducing healing time and improving final visual acuity while reducing the need for tectonic keratoplasty" noted the study authors.
It can be challenging to cross-link the eyes of wheelchair users – for the patient and clinic staff alike. Slit lamp CXL could be the answer!